When Should We Adopt EUS-Guided Radiofrequency Ablation in Pancreatic Neuroendocrine Tumors?
Pancreatic neuroendocrine neoplasms (PanNENs) are rare and heterogeneous diseases that account for less than 2% of all cases of pancreatic cancer and only 30% of digestive neuroendocrine neoplasia, even if their incidence and prevalence continue to rise globally [...]
Main Authors: | Matteo Marasco, Domenico Galasso, Alberto Larghi, Francesco Panzuto |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-07-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/12/14/4581 |
Similar Items
-
EUS-guided radiofrequency ablation of a pancreatic neuroendocrine tumor
by: Qais Dawod, MD, et al.
Published: (2020-05-01) -
Long-term outcome after EUS-guided radiofrequency ablation: Prospective results in pancreatic neuroendocrine tumors and pancreatic cystic neoplasms
by: Marc Barthet, et al.
Published: (2021-07-01) -
Novel EUS-guided microwave ablation of an unresectable pancreatic neuroendocrine tumor
by: Carlos Robles-Medranda, MD, et al.
Published: (2022-02-01) -
A Review on Endoscopic Ultrasound-Guided Radiofrequency Ablation (EUS-RFA) of Pancreatic Lesions
by: Fred G. Karaisz, et al.
Published: (2023-02-01) -
Endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) for advanced pancreatic and periampullary adenocarcinoma
by: Nirav Thosani, et al.
Published: (2022-10-01)